Johnson & Johnson (JNJ)
| Market Cap | 377.32B |
| Revenue (ttm) | 95.33B |
| Net Income (ttm) | 34.62B |
| Shares Out | 2.41B |
| EPS (ttm) | 13.46 |
| PE Ratio | 11.64 |
| Forward PE | 14.73 |
| Dividend | $4.76 (3.04%) |
| Ex-Dividend Date | Nov 20, 2023 |
| Volume | 2,796,702 |
| Open | 156.51 |
| Previous Close | 156.58 |
| Day's Range | 155.98 - 156.90 |
| 52-Week Range | 144.95 - 180.93 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 167.73 (+7.01%) |
| Earnings Date | Jan 23, 2024 |
About JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NI... [Read more]
Financial Performance
In 2022, JNJ's revenue was $94.94 billion, an increase of 1.25% compared to the previous year's $93.78 billion. Earnings were $17.94 billion, a decrease of -14.07%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $167.73, which is an increase of 7.01% from the latest price.
News
Judge certifies Johnson & Johnson shareholder class action over talc disclosures
A federal judge said Johnson & Johnson shareholders may pursue as a class action their lawsuit accusing the company of concealing how its talc products were contaminated by asbestos.
Stock Movers: J&J, Vertex Pharma and Tesla
The “Halftime Report” Investment Committee debate the market movers they own.
Cramer's Mad Dash: Johnson & Johnson
CNBC's Jim Cramer delivers his daily Mad Dash.
Key Talc Lawyers: Planned “Prepack” J&J Bankruptcy is “Farce” and Improper Litigation Tactic
MONTGOMERY, Ala.--(BUSINESS WIRE)--Attorneys representing ovarian cancer victims who are suing Johnson & Johnson (NYSE: JNJ) warn that J&J's declared bankruptcy strategy to end talc litigation will no...
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 23rd to review fourth-quarter results. Joa...
Johnson & Johnson to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8th, at the Westin St. Francis in San Franc...
J&J says it has settled some talc claims, will continue bankruptcy strategy
Johnson & Johnson's worldwide vice president for litigation said on Tuesday that the company has recently reached settlements with several law firms over their clients' claims that J&J talc products c...
StemPoint's Michelle Ross is bullish on J&J after stronger guidance
Michelle Ross, StemPoint Capital CIO, joins 'Closing Bell' to discuss biotech, weight-loss drugs and her playbook.
Publication in Bloomberg Law: ‘A Third J&J Bankruptcy Attempt Won't Resolve Victims' Talc Claims' by Andy Birchfield
MONTGOMERY, Ala.--(BUSINESS WIRE)--In a compelling new article published in Bloomberg Law, attorney Andy Birchfield, who leads the mass torts section at the Beasley Allen Law Firm, delves into the ong...
J&J CEO Joaquin Duato on 2024 guidance, product pipeline and long-term growth outlook
Johnson & Johnson chairman and CEO Joaquin Duato, joins 'Squawk Box' to discuss the company's long-term competitive growth plan, 2024 guidance, the implementation and impact of A.I. and machine learni...
Johnson & Johnson Ticks Higher Following Guidance Release
The pharmaceutical and medical-device company offered long-term targets at an investor meeting.
J&J's stock slightly higher as company offers guidance for 2024 and longer term
Johnson & Johnson's stock JNJ, +0.32% was slightly higher premarket Tuesday, after the healthcare company set guidance for 2024 and for the longer term, ahead of an investor day at the New York Stock ...
Johnson & Johnson forecasts as much as 6% sales growth in 2024
Johnson & Johnson on Tuesday forecast revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara...
Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the ‘Company') is hosting a meeting today with the investment community at the New York Stock Exchange to present the Company's ove...
Johnson & Johnson Stock Gains a Bull Ahead of Analyst Day
Shares are lower this year, thanks to an ongoing legal situation, but UBS says those worries are factored into the stock.
Cramer's Stop Trading: Johnson & Johnson
CNBC's Jim Cramer explains why he is keeping an eye on shares of Johnson & Johnson.
Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that Eugene A. Woods, MBA, MHA, Chief Executive Officer of Advocate Health, has been appointed to its Board of Direc...
Johnson & Johnson buys medical device maker Laminar, cuts full-year earnings guidance
Johnson & Johnson JNJ, +0.32% said Thursday that its medical technology segment has acquired medical device maker Laminar Inc. in a deal that will reduce its full-year 2023 and 2024 earnings per share...
Johnson & Johnson MedTech Acquires Laminar, Inc.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the...
J&J, Gilead, BMS: A look at undervalued dividend payers
Johnson & Johnson NYSE: JNJ, Gilead Sciences Inc. NYSE: GILD and Bristol Myers Squibb Co. NYSE: BMY are among healthcare sector dividend-payers trading at low valuations relative to their earnings.
2023's most anticipated IPOs weren't always the big winners
So far in 2023, 146 companies have gone public in the U.S. markets, down 16.09% from the same time last year. Although the IPO market has been choppy amid higher interest rates and broad equity market...
5 Best Blue-Chip Stocks For 2024
Here's a look at the anatomy of blue-chips stocks along with five top picks for the upcoming year.